Optic Nerve Disorders Treatment Market

Optic Nerve Disorders Treatment Market (Treatment Type: Pharmacological Treatment (Prostaglandin, Beta Interferons, Beta Blockers, Alpha-adrenergic Agonist, Carbonic Anhydrase Inhibitors, Corticosteroids, Combination Drugs, and Others), and Surgery; Indication: Glaucoma, Optic Neuritis, Optic Neuropathy (Arteritic Ischemic Optic Neuropathy, Non-arteritic Ischemic Optic Neuropathy, and Congenital Optic Atrophy), and Others; and End User: Hospitals, Ambulatory Surgery Centers, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

New Treatment Options for Glaucoma through Precision Medicines and Topical Treatments in Offing

Emergence of topical treatments are creating incremental opportunities for manufacturers operating in the optic nerve disorders treatment market. For instance, Canadian manufacturers of eye health products Bausch & Lomb, announced the launch of VYZULTA® — a topical glaucoma treatment solution that gained acceptance by the Government of Canada.

Companies in the optic nerve disorders treatment market are increasing treatment options for glaucoma, since the glaucoma indication segment of the optic nerve disorders treatment market is projected for exponential growth during the forecast period. The glaucoma segment is expected to reach a value of ~US$ 12.1 Bn by the end of 2023. Hence, manufacturers are increasing efficacy in precision medication to offer treatment options for glaucoma.

To innovate in precision medicines, manufacturers in the market for optic nerve disorders treatment are increasing research to understand the aqueous humor for anterior segment and trabecular meshwork tissue.

optic nerve disorders treatment market infographic

To know the scope of our report Get a Sample on Optic Nerve Disorders Treatment Market ?

Advancements in Beta Interferons Benefit MS Patients

High prevalence of multiple sclerosis (MS) patients is one of the key drivers for the growth of optic nerve disorders treatment market. Hence, manufacturers are increasing production capabilities to develop immunosuppressive drugs that improve quality of life in patients. For instance, in September 2019, Swiss multinational healthcare company Roche revealed its proceedings on trials for OCREVUS® — an immunosuppressive drug, to understand its effects in relapsing and progressive MS.

Companies in the optic nerve disorders treatment market are increasing trials of immunosuppressive drugs with beta interferons to provide relief to MS patients. As such, the beta interferons sub-segment of the pharmacological treatment segment is estimated to reach a value of ~US$ 2.5 Bn by 2027. Hence, manufacturers in the optic nerve disorders treatment market are increasing production capabilities in beta interferons, since pharmacological treatment segment is anticipated for aggressive growth during the forecast period. Moreover, the neurofilament light chain-lowering capabilities of beta interferons are increasingly benefitting MS patients.

Get a glimpse of the in-depth analysis through our Report Brochure

Companies Focus on Unmet Needs of NMOSD Patients in Europe

New drugs for rare neurologic eye diseases are being extensively researched for the treatment of MS and neuromyelitis optica. Striking correlation between neurologic diseases and rare eye conditions have opened the doors for innovation in the optic nerve disorders treatment market.

On the other hand, terminal complement inhibitors are under scrutiny of the European and Japanese health commissions. As such, companies are focusing to extend their product portfolios into Europe and Japan, since the two regions are projected for exponential growth during the forecast period. For instance, in June 2019, Alexion — a U.S. pharmaceutical company, announced that the European Medicines Agency and Japanese Ministry of Health, Labor and Welfare are assessing applications of SOLIRIS® for the treatment of neuromyelitis optica spectrum disorder (NMOSD).

The optic nerve disorders treatment market in Europe is expected to reach a value of ~US$ 4.2 Bn. Thus, manufacturers in the market for optic nerve disorders treatment are focusing on meeting the needs of patients in Europe, since NMOSD is a rare disease.

Innovations in Corticosteroids Meet Post Ocular Surgery Requirements

Innovations in topical ocular corticosteroids are proving to be beneficial for patients in the management of pain and inflammation post ocular surgery. However, limitations of these corticosteroids, such as limited bioavailability and class-associated adverse events (AE) are some of the barriers that companies in the optic nerve disorders treatment market have to counter. Hence, manufacturers in the optic nerve disorders treatment market are educating healthcare providers about drug-specific variables of topical ocular corticosteroids, such as AE profile, potency, and patient-specific administration needs for better outcomes in patients.

Companies in the market for optic nerve disorders treatment are aiming at minimizing precorneal drug loss and maximizing drug delivery to the anterior tissues with the help of improved corticosteroid formulations. They are adopting various strategies to enhance ocular penetration by including mucoadhesive formulations in the development of new corticosteroids. Strategies, such as drug-particle size reduction enable faster drug dissolution, which increases bioavailability and penetration. Hence, companies in the optic nerve disorders treatment market are increasing the production capacities of loteprednol etabonate corticosteroids using retrometabolic drug design.

optic nerve disorders treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Companies in the optic nerve disorders treatment market are tapping into new opportunities to obtain new clues from drugs used in neurological disorders for treatment of vision-related diseases. For instance, in May 2019, Bionure — a Spanish biotechnology company, announced its successful investigation for its neuroprotectant BN201, which holds promising results in the treatment of MS and acute optic neuritis.

However, poor bioavailability of drugs for efficacious ocular drug delivery poses as a challenge for manufacturers. Hence, companies should innovate in ocular therapeutics to improve biopharmaceutical properties of drugs. They should focus on expanding product portfolio of drugs that treat optic neuritis, since this indication is projected to gain significant prominence during the forecast period.

Optic Nerve Disorders Treatment Market: Overview

  • Increase in prevalence of eye disorders is the major driver of the global optic nerve disorders treatment market
  • Optic nerve disorders treatment covers treatment options for optic nerve disorders, which include pharmacological treatment consisting of medications and surgery
  • Glaucoma is one of the major indications resulting from optic nerve damage and is a common ophthalmologic condition
  • Optic nerve disorders are caused due to the damage to optic nerves, which can result in vision loss and eventually complete blindness
  • These disorders include glaucoma, optic neuritis, optic neuropathy, idiopathic intracranial hypertension, optic nerve drusen, and other disorders associated with the optic nerves
  • According to the American Academy of Ophthalmology, in 2011, 2.71 million people in the U.S. had primary open-angle glaucoma (POAG)
  • Growing aging population prone to ophthalmological conditions, and high adoption rate and usage of digital devices are some of the concerning factors leading to eye related disorders

Optic Nerve Disorders Treatment Market: Segmentation

  • Based on treatment type, the optic nerve disorders treatment market has been bifurcated into pharmacological treatment and surgery
  • Pharmacological treatment has been further classified into prostaglandins, beta interferons, beta blockers, alpha-adrenergic agonist, carbonic anhydrase inhibitors, corticosteroids, combination drugs, and others
  • In terms of indication, the optic nerve disorders treatment market has been segmented into glaucoma, optic neuritis, optic neuropathy, and others
  • Optic neuropathy segment has been further sub-segmented into arteritic ischemic optic neuropathy, non-arteritic ischemic optic neuropathy, and congenital optic atrophy
  • In terms of end user, the optic nerve disorders treatment market has been segmented into hospitals, ambulatory surgery centers, clinics, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights
  • The report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment, along with the market size estimations for the period 2019 to 2027.

Optic Nerve Disorders Treatment Market: Regional Overview

  • In terms of region, the optic nerve disorders treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
  • The current and future market size, in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period 2019 to 2027
  • The study also offers a list of recommendations, highlights, and useful market insights, which will help new companies planning to enter the market and existing companies to increase market share, and help in the decision-making process

Major Players in Global Market

  • The report concludes with the company profiles section that includes key information about the major players in the optic nerve disorders treatment market
  • Key players analyzed in this report are
    • Santen Pharmaceutical Co., Ltd.,
    • Allergan plc.
    • Novartis AG
    • Pfizer, Inc.
    • Bausch Health Companies, Inc.
    • Aerie Pharmaceuticals, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bionure Farma, S.L.
    • Mallinckrodt Pharmaceuticals
  •  Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Optic Nerve Disorders Treatment Market – Segmentation

TMR’s study on the optic nerve disorders treatment market includes information divided into four sections ? treatment type, indication, end user, and region. Changing industry trends and other crucial market dynamics associated with these sections of the optic nerve disorders treatment market have been discussed in detail.

Treatment Type

  • Pharmacological Treatment
    • Prostaglandins
    • Beta Interferons
    • Beta Blockers
    • Alpha-adrenergic Agonists
    • Carbonic Anhydrase Inhibitors
    • Corticosteroids
    • Combination Drugs
    • Others
  • Surgery

Indication

  • Glaucoma
  • Optic Neuritis
  • Optic Neuropathy
    • Arteritic Ischemic Optic Neuropathy
    • Non-arteritic Ischemic Optic Neuropathy
  • Congenital Optic Atrophy
  • Others

End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Clinics
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of optic nerve disorders treatment market?

Optic nerve disorders treatment market to reach a valuation of ~US$ 19.5 Bn by 2027

What is the anticipated CAGR of the optic nerve disorders treatment market in the forecast period?

Optic nerve disorders treatment market is expected to expand at a CAGR of ~4% during the forecast period from 2019 to 2027

What are the key driving factors for the growth of the optic nerve disorders treatment market?

Optic nerve disorders treatment market is driven by increase in prevalence of eye disorders

Which region is expected to project the highest market share in the global optic nerve disorders treatment market?

North America accounted for a major share of the optic nerve disorders treatment market, and is projected to remain dominant during the forecast period

Who are the key players in the global optic nerve disorders treatment market?

Key players in the global optic nerve disorders treatment market include Santen Pharmaceutical Co., Ltd., Allergan plc. Novartis AG, Pfizer, Inc., Bausch Health Companies

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Optic Nerve Disorders Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Treatment Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Market Outlook

        5.1. Pipeline Analysis

        5.2. Key Vendor and Distributor Analysis

        5.3. Technological Advancements

        5.4. Prevalence & Incidence of Optic Nerve Disorders

        5.5. Regulatory Scenario Assessment

    6. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Treatment Type 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Treatment Type, 2017–2027

            6.3.1. Pharmacological Treatment

                6.3.1.1. Prostaglandins

                6.3.1.2. Beta Interferons

                6.3.1.3. Beta Blockers

                6.3.1.4. Alpha-adrenergic Agonist

                6.3.1.5. Carbonic Anhydrase Inhibitors

                6.3.1.6. Corticosteroids

                6.3.1.7. Combination Drugs

                6.3.1.8. Others

            6.3.2. Surgery

        6.4. Market Attractiveness By Treatment Type, 2019-2027

    7. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Indication 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Indication, 2017–2027

            7.3.1. Glaucoma

            7.3.2. Optic Neuritis

            7.3.3. Optic Neuropathy

                7.3.3.1. Arteritic ischemic optic neuropathy

                7.3.3.2. Non-arteritic ischemic optic neuropathy

                7.3.3.3. Congenital Optic Atrophy

            7.3.4. Others

        7.4. Market Attractiveness By Indication, 2019-2027

    8. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By End-user 

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By End-user, 2017–2027

            8.3.1. Hospitals

            8.3.2. Ambulatory Surgery Centers

            8.3.3. Clinics

            8.3.4. Others

        8.4. Market Attractiveness By End-user, 2019-2027

    9. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Region

        9.1. Key Findings

        9.2. Market Value Forecast By Region

            9.2.1. North America 

            9.2.2. Europe 

            9.2.3. Asia Pacific 

            9.2.4. Latin America 

            9.2.5. Middle East & Africa 

        9.3. Market Attractiveness By Country/Region, 2019-2027

    10. North America Optic Nerve Disorders Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast By Treatment Type, 2017–2027

            10.2.1. Pharmacological Treatment

                10.2.1.1. Prostaglandins

                10.2.1.2. Beta Interferons

                10.2.1.3. Beta Blockers

                10.2.1.4. Alpha-adrenergic Agonist

                10.2.1.5. Carbonic Anhydrase Inhibitors

                10.2.1.6. Corticosteroids

                10.2.1.7. Combination Drugs

                10.2.1.8. Others

            10.2.2. Surgery

        10.3. Market Value Forecast By Indication, 2017–2027

            10.3.1. Glaucoma

            10.3.2. Optic Neuritis

            10.3.3. Optic Neuropathy

                10.3.3.1. Arteritic ischemic optic neuropathy

                10.3.3.2. Non-arteritic ischemic optic neuropathy

                10.3.3.3. Congenital Optic Atrophy

            10.3.4. Others

        10.4. Market Value Forecast By End-user, 2017–2027

            10.4.1. Hospitals

            10.4.2. Ambulatory Surgery Centers

            10.4.3. Clinics

            10.4.4. Others

        10.5. Market Value Forecast By Country, 2017–2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis 

            10.6.1. By Treatment Type 

            10.6.2. By Indication 

            10.6.3. By End-user 

            10.6.4. By Country

    11. Europe Optic Nerve Disorders Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast by Treatment Type, 2017–2027

            11.2.1. Pharmacological Treatment

                11.2.1.1. Prostaglandins

                11.2.1.2. Beta Interferons

                11.2.1.3. Beta Blockers

                11.2.1.4. Alpha-adrenergic Agonist

                11.2.1.5. Carbonic Anhydrase Inhibitors

                11.2.1.6. Corticosteroids

                11.2.1.7. Combination Drugs

                11.2.1.8. Others

            11.2.2. Surgery

        11.3. Market Value Forecast by Indication, 2017–2027

            11.3.1. Glaucoma

            11.3.2. Optic Neuritis

            11.3.3. Optic Neuropathy

                11.3.3.1. Arteritic ischemic optic neuropathy

                11.3.3.2. Non-arteritic ischemic optic neuropathy

                11.3.3.3. Congenital Optic Atrophy

            11.3.4. Others

        11.4. Market Value Forecast by End-user, 2017–2027

            11.4.1. Hospitals

            11.4.2. Ambulatory Surgery Centers

            11.4.3. Clinics

            11.4.4. Others

        11.5. Market Value Forecast by Country/Sub-region, 2017–2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis 

            11.6.1. By Treatment Type 

            11.6.2. By Indication 

            11.6.3. By End-user 

            11.6.4. By Country

    12. Asia Pacific Optic Nerve Disorders Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast by Treatment Type, 2017–2027

            12.2.1. Pharmacological Treatment

                12.2.1.1. Prostaglandins

                12.2.1.2. Beta Interferons

                12.2.1.3. Beta Blockers

                12.2.1.4. Alpha-adrenergic Agonist

                12.2.1.5. Carbonic Anhydrase Inhibitors

                12.2.1.6. Corticosteroids

                12.2.1.7. Combination Drugs

                12.2.1.8. Others

            12.2.2. Surgery

        12.3. Market Value Forecast by Indication, 2017–2027

            12.3.1. Glaucoma

            12.3.2. Optic Neuritis

            12.3.3. Optic Neuropathy

                12.3.3.1. Arteritic ischemic optic neuropathy

                12.3.3.2. Non-arteritic ischemic optic neuropathy

                12.3.3.3. Congenital Optic Atrophy

            12.3.4. Others

        12.4. Market Value Forecast by End-user, 2017–2027

            12.4.1. Hospitals

            12.4.2. Ambulatory Surgery Centers

            12.4.3. Clinics

            12.4.4. Others

        12.5. Market Value Forecast by Country/Sub-region, 2017–2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis 

            12.6.1. By Treatment Type 

            12.6.2. By Indication 

            12.6.3. By End-user 

            12.6.4. By Country

    13. Latin America Optic Nerve Disorders Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast by Treatment Type, 2017–2027

            13.2.1. Pharmacological Treatment

                13.2.1.1. Prostaglandins

                13.2.1.2. Beta Interferons

                13.2.1.3. Beta Blockers

                13.2.1.4. Alpha-adrenergic Agonist

                13.2.1.5. Carbonic Anhydrase Inhibitors

                13.2.1.6. Corticosteroids

                13.2.1.7. Combination Drugs

                13.2.1.8. Others

            13.2.2. Surgery

        13.3. Market Value Forecast by Indication, 2017–2027

            13.3.1. Glaucoma

            13.3.2. Optic Neuritis

            13.3.3. Optic Neuropathy

                13.3.3.1. Arteritic ischemic optic neuropathy

                13.3.3.2. Non-arteritic ischemic optic neuropathy

                13.3.3.3. Congenital Optic Atrophy

            13.3.4. Others

        13.4. Market Value Forecast by End-user, 2017–2027

            13.4.1. Hospitals

            13.4.2. Ambulatory Surgery Centers

            13.4.3. Clinics

            13.4.4. Others

        13.5. Market Value Forecast By Country/Sub-region, 2017–2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis 

            13.6.1. By Treatment Type 

            13.6.2. By Indication 

            13.6.3. By End-user 

            13.6.4. By Country

    14. Middle East & Africa Optic Nerve Disorders Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast by Treatment Type, 2017–2027

            14.2.1. Pharmacological Treatment

                14.2.1.1. Prostaglandins

                14.2.1.2. Beta Interferons

                14.2.1.3. Beta Blockers

                14.2.1.4. Alpha-adrenergic Agonist

                14.2.1.5. Carbonic Anhydrase Inhibitors

                14.2.1.6. Corticosteroids

                14.2.1.7. Combination Drugs

                14.2.1.8. Others

            14.2.2. Surgery

        14.3. Market Value Forecast by Indication, 2017–2027

            14.3.1. Glaucoma

            14.3.2. Optic Neuritis

            14.3.3. Optic Neuropathy

                14.3.3.1. Arteritic ischemic optic neuropathy

                14.3.3.2. Non-arteritic ischemic optic neuropathy

                14.3.3.3. Congenital Optic Atrophy

            14.3.4. Others

        14.4. Market Value Forecast by End-user, 2017–2027

            14.4.1. Hospitals

            14.4.2. Ambulatory Surgery Centers

            14.4.3. Clinics

            14.4.4. Others

        14.5. Market Value Forecast by Country/Sub-region, 2017–2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis 

            14.6.1. By Treatment Type 

            14.6.2. By Indication 

            14.6.3. By End-user 

            14.6.4. By Country

    15. Competition Landscape

        15.1. Market Player – Competition Matrix (By Tier and Size of companies)

        15.2. Market Position/Ranking Analysis, By Tier and Size of the Company (2018)

        15.3. Company Profiles

            15.3.1. Santen Pharmaceutical Co., Ltd.

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Company Financials

                15.3.1.3. Growth Strategies

                15.3.1.4. SWOT Analysis

            15.3.2. Allergan plc.

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Company Financials

                15.3.2.3. Growth Strategies

                15.3.2.4. SWOT Analysis

            15.3.3. Novartis AG

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Company Financials

                15.3.3.3. Growth Strategies

                15.3.3.4. SWOT Analysis

            15.3.4. Pfizer, Inc.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Company Financials

                15.3.4.3. Growth Strategies

                15.3.4.4. SWOT Analysis

            15.3.5. Bausch Health Companies, Inc.

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Company Financials

                15.3.5.3. Growth Strategies

                15.3.5.4. SWOT Analysis

            15.3.6. Aerie Pharmaceuticals, Inc.

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Company Financials

                15.3.6.3. Growth Strategies

                15.3.6.4. SWOT Analysis

            15.3.7. Teva Pharmaceutical Industries Ltd.

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Company Financials

                15.3.7.3. Growth Strategies

                15.3.7.4. SWOT Analysis

            15.3.8. Bionure Farma, S.L.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Company Financials

                15.3.8.3. Growth Strategies

                15.3.8.4. SWOT Analysis

            15.3.9. Mallinckrodt Pharmaceuticals

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Company Financials

                15.3.9.3. Growth Strategies

                15.3.9.4. SWOT Analysis

    List of Tables

    Table 01: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

    Table 02: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

    Table 03: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

    Table 04: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

    Table 05: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

    Table 06: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027 

    Table 07: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027 

    Table 08: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

    Table 09: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

    Table 10: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

    Table 11: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

    Table 12: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

    Table 13: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

    Table 14: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

    Table 15: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

    Table 16: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

    Table 17: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

    Table 18: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

    Table 19: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

    Table 20: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

    Table 21: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

    Table 22: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

    Table 23: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

    Table 24: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

    Table 25: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

    Table 26: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

    Table 27: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

    Table 28: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

    Table 29: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

    Table 30: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027 

    Table 31: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

    Table 32: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027 

    Table 33: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027 

    Table 34: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027 

    Table 35: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027 

    Table 36: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    List of Figures

    Figure 01: Global Optic Nerve Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 02: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2027

    Figure 03: Global Optic Nerve Disorders Treatment Market Value Share, by Treatment Type (2018)

    Figure 04: Global Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment (2018)

    Figure 05: Global Optic Nerve Disorders Treatment Market Value Share, by Indication (2018)

    Figure 06: Global Optic Nerve Disorders Treatment Market Value Share, by End-user (2018)

    Figure 07: Global Optic Nerve Disorders Treatment Market Value Share, by Region (2018)

    Figure 08: Regulatory Approval Process - The U.S.  

    Figure 09: Regulatory Approval Process - Europe 

    Figure 10: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027

    Figure 11: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Pharmacological Treatment, 2018 and 2027

    Figure 12: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacological Treatment, 2017–2027

    Figure 13: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgery, 2017–2027

    Figure 14: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prostaglandins, 2017-2027

    Figure 15: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Interferons, 2017-2027

    Figure 16: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2017-2027

    Figure 17: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Alpha-adrenergic agonist, 2017-2027

    Figure 18: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Carbonic Anhydrase Inhibitors, 2017-2027

    Figure 19: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroidss, 2017-2027

    Figure 20: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Combination Drugs, 2017-2027

    Figure 21: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 22: Global Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027

    Figure 23: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Indication, 2018 and 2027

    Figure 24: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glaucoma, 2017-2027

    Figure 25: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Optic Neuritis, 2017-2027

    Figure 26: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Optic Neuropathy, 2017-2027

    Figure 27: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 28: Global Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027

    Figure 29: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 30: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027

    Figure 31: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ambulatory Surgery Centers, 2017–2027

    Figure 32: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2017–2027

    Figure 33: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Academic & Research Institutes, 2017–2027

    Figure 34: Global Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027

    Figure 35: Global Optic Nerve Disorders Treatment Market Value Share, by Region, 2018 and 2027

    Figure 36: Global Optic Nerve Disorders Treatment Market Attractiveness, by Region, 2019–2027

    Figure 37: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 38: North America Optic Nerve Disorders Treatment Market Value Share, by Country, 2018 and 2027

    Figure 39: North America Optic Nerve Disorders Treatment Market Attractiveness, by Country, 2019–2027

    Figure 40: North America Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

    Figure 41: North America Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

    Figure 42: North America Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027

    Figure 43: North America Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

    Figure 44: North America Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

    Figure 45: North America Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

    Figure 46: North America Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

    Figure 47: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 48: Europe Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

    Figure 49: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027 

    Figure 50: Europe Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

    Figure 51: Europe Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

    Figure 52: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027

    Figure 53: Europe Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

    Figure 54: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

    Figure 55: Europe Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

    Figure 56: Europe Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

    Figure 57: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 58: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

    Figure 59: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027 

    Figure 60: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

    Figure 61: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

    Figure 62: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027

    Figure 63: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

    Figure 64: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

    Figure 65: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

    Figure 66: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

    Figure 67: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 68: Latin America Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

    Figure 69: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 70: Latin America Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

    Figure 71: Latin America Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

    Figure 72: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027

    Figure 73: Latin America Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

    Figure 74: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

    Figure 75: Latin America Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

    Figure 76: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

    Figure 77: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

    Figure 78: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027 

    Figure 79: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 80: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027

    Figure 81: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027

    Figure 82: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027

    Figure 83: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027

    Figure 84: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027 

    Figure 85: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027 

    Figure 86: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027 

    Figure 87: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Copyright © Transparency Market Research, Inc. All Rights reserved